Teva Pharma Industries Ltd ADR (TEVA)vsAlpha Teknova Inc (TKNO)
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
TKNO
Alpha Teknova Inc
$3.04
+2.01%
HEALTHCARE · Cap: $159.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 42491% more annual revenue ($17.26B vs $40.52M). TEVA leads profitability with a 8.2% profit margin vs -42.6%. TEVA earns a higher WallStSmart Score of 73/100 (B).
TEVA
Strong Buy73
out of 100
Grade: B
TKNO
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Intrinsic value data unavailable for TKNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -22.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity, Price/Book.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
TEVA profiles as a value stock while TKNO is a turnaround play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.72 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 31/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading provider of synthetic biology solutions, specializing in high-quality biological reagents and supplements essential for life sciences research and biomanufacturing. The company addresses critical needs across key sectors, such as vaccine development, cell and gene therapy, and diagnostic testing, while maintaining a steadfast commitment to quality and customer service excellence. With a robust foundation in biotechnology and a focus on innovation, Alpha Teknova is well-positioned to capitalize on the expanding opportunities within the life sciences market, fostering growth and delivering value to its investors.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?